RxDoctor Payments Data

Lorena de Alejandro

Family · Peoria, AZNPI 1043720923

Payments from drug & device makers

$2,736in general payments, 2019–2025

Across 96 payments — averaging $28.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$258
  • Phathom Pharmaceuticals, Inc.$230
  • Novo Nordisk$222
  • Astellas Pharma US Inc$217
  • AstraZeneca$211
  • Boston Scientific$191
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,736100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,736 in reported general payments places this provider in the 85th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$58,633
Medicare patients
257
Services billed
726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$69,519
JardianceEmpagliflozin58$65,035
EliquisApixaban25$40,688
FarxigaDapagliflozin Propanediol35$31,826
TrulicityDulaglutide13$18,907
MounjaroTirzepatide14$16,062
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$10,597
Tresiba Flextouch U-100Insulin Degludec12$6,311
Atorvastatin Calcium205$2,277
Albuterol Sulfate HfaAlbuterol Sulfate62$1,662
Rosuvastatin Calcium95$1,406
Levothyroxine Sodium106$1,251
SynthroidLevothyroxine Sodium16$1,117
Losartan Potassium91$1,030
Amlodipine Besylate112$975

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$222$69,51942 claims
Boehringer IngelheimJardiance$40$65,03558 claims
AstraZenecaFarxiga, Breztri Aerosphere$211$42,42448 claims
PfizerEliquis$168$40,68825 claims
Lilly USA, LLCTrulicity, Mounjaro$178$34,96927 claims
AbbVieSynthroid$140$1,11716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,119 family providers in Arizona.

Other family in Peoria

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →